Research Summary

Dr. Aaron Logan is an Associate Professor of Clinical Medicine at the University of California, San Francisco (UCSF). His clinical practice focuses on the management of patients with acute leukemias, myelodysplastic syndrome, aplastic anemia and hemophagocytic lymphohistiocytosis. Dr. Logan also runs a research laboratory and is director of the Hematologic Malignancies Tissue Bank at UCSF. Dr. Logan and his laboratory are interested in methods for evaluating clonotypic diversity in the B and T lymphocyte repertoires in patients, particularly following hematopoietic cell transplantation when used to treat blood cancers, bone marrow failure disorders, and congenital immune deficiencies. Methods used in the laboratory currently include T cell receptor excision circle and kappa-deleting recombination circle (TREC/KREC) quantification, high-throughput sequencing of immunoglobulin and T cell receptor genes, and in vitro mixed lymphocyte reactions to identify T cells with specific reactivities. Efforts in the lab are focused on the application of immune repertoire profiling to quantify and track malignancy-, pathogen-, and autoantigen-targeted immune responses following allogeneic transplantation, as well as use of this platform to quantify measurable residual disease in lymphoid malignancies. In Dr. Logan’s lab, the Hematologic Malignancies Tissue Bank at UCSF has been built into a robust resource for samples isolated from patients with a wide diversity of blood cancers and following transplantation. These samples are made available in a deidentified manner to the UCSF and larger research community for cooperative discovery.

Education

Hematology and Blood and Marrow Transplant Fellowships, Stanford University, 2013
Internal Medicine Residency (Clinical Investigator Pathway), Stanford University, 2008
MD, Keck School of Medicine of the University of Southern California, 2006
PhD, Molecular Microbiology and Immunology, Keck School of Medicine of the University of Southern California, 2006
MPhil, History of Medicine, University of Cambridge, England

Honors & Awards

  • 2020
    UCSF Hematology-Oncology Fellowship Teaching Award
  • 2012
    Abstract Award, American Society of Hematology
  • 2011
    Abstract Award, American Society of Hematology
  • 2011
    Research Training Award for Fellows, American Society of Hematology
  • 2011
    Clinical Research Training Fellow, American Society of Blood and Marrow Transplantation
  • 2006
    Highest Distinction, Keck School of Medicine of the University of Southern California
  • 2005
    Alpha Omega Alpha
  • 2005
    Dean's Recognition, Keck School of Medicine of the University of Southern California
  • 2004
    Travel Award, American Society of Gene Therapy
  • 2003
    Outstanding Teaching Award, Keck School of Medicine of the University of Southern California
  • 2003
    Excellence in Teaching in Cell and Neurobiology, Keck School of Medicine of the University of Southern California

Selected Publications

  1. Kantarjian HM, Logan AC, Zaman F, Gökbuget N, Bargou RC, Zeng Y, Zugmaier G, Locatelli F. Survival outcomes in patients with relapsed/refractory or MRD-positive B-cell acute lymphoblastic leukemia treated with blinatumomab. Ther Adv Hematol. 2023; 14:20406207231201454.  View on PubMed
  2. Gaut D, Oliai C, Boiarsky J, Zhang S, Salhotra A, Azenkot T, Kennedy VE, Khanna V, Olmedo Gutierrez K, Shukla N, Moskoff B, Park G, Afkhami M, Patel A, Jeyakumar D, Mannis G, Logan AC, Jonas BA, Schiller G. Measurable residual disease conversion rate with consolidation chemotherapy in acute myeloid leukemia. Leuk Lymphoma. 2023 Oct 06; 1-9.  View on PubMed
  3. Huang LW, Shi Y, Andreadis C, Logan AC, Mannis GN, Smith CC, Gaensler KML, Martin TG, Damon LE, Boscardin WJ, Steinman MA, Olin RL. Association of geriatric measures and global frailty with cognitive decline after allogeneic hematopoietic cell transplantation in older adults. J Geriatr Oncol. 2023 Sep 05; 14(8):101623.  View on PubMed
  4. Shah BD, Cassaday RD, Park JH, Houot R, Oluwole OO, Logan AC, Boissel N, Leguay T, Bishop MR, Topp MS, Tzachanis D, O'Dwyer KM, Arellano ML, Lin Y, Baer MR, Schiller GJ, Subklewe M, Abedi M, Minnema MC, Wierda WG, DeAngelo DJ, Stiff PJ, Jeyakumar D, Mao D, Adhikary S, Zhou L, Schuberth PC, Damico Khalid R, Ghobadia A. Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3. J Immunother Cancer. 2023 Aug; 11(8).  View on PubMed
  5. Lee JC, Logan AC. Diagnosis and Management of Adult Malignancy-Associated Hemophagocytic Lymphohistiocytosis. Cancers (Basel). 2023 Mar 18; 15(6).  View on PubMed
  6. Banerjee R, Kelkar AH, Durani U, Anagnostou T, Nishitani M, Mallhi K, Majhail NS, Logan AC. Demographics, Motivations, and Experiences of Participants in Transplantation or Cellular Therapy Fellowships. Transplant Cell Ther. 2023 06; 29(6):394.e1-394.e7.  View on PubMed
  7. Logan AC. Lower leukemia burden maximizes the impact of blinatumomab therapy. Cancer. 2023 05 01; 129(9):1316-1318.  View on PubMed
  8. Aldoss I, Shah BD, Park JH, Muffly L, Logan AC, Brown P, Stock W, Jabbour EJ. Sequencing antigen-targeting antibodies and cellular therapies in adults with relapsed/refractory B-cell acute lymphoblastic leukemia. Am J Hematol. 2023 04; 98(4):666-680.  View on PubMed
  9. Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD, Leguay T, Bishop MR, Topp MS, Tzachanis D, O'Dwyer KM, Arellano ML, Lin Y, Baer MR, Schiller GJ, Park JH, Subklewe M, Abedi M, Minnema MC, Wierda WG, DeAngelo DJ, Stiff P, Jeyakumar D, Dong J, Adhikary S, Zhou L, Schuberth PC, Faghmous I, Masouleh BK, Houot R. Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study. J Hematol Oncol. 2022 12 10; 15(1):170.  View on PubMed
  10. Logan AC. Measurable residual disease in acute lymphoblastic leukemia: How low is low enough? Best Pract Res Clin Haematol. 2022 Dec; 35(4):101407.  View on PubMed
  11. Ferng TT, Terada D, Ando M, Tarver TC, Chaudhary F, Lin KC, Logan AC, Smith CC. The Irreversible FLT3 Inhibitor FF-10101 Is Active Against a Diversity of FLT3 Inhibitor Resistance Mechanisms. Mol Cancer Ther. 2022 05 04; 21(5):844-854.  View on PubMed
  12. Kennedy VE, Hui G, Azenkot T, Gaut D, Wieduwilt MJ, Oliai C, Jonas BA, Mittal V, Logan AC, Muffly LS, Mannis GN. Outcomes of allogeneic transplantation after hypomethylating agents with venetoclax in acute myeloid leukemia. Am J Hematol. 2022 06 01; 97(6):E191-E194.  View on PubMed
  13. Logan AC. SOHO State of the Art Updates and Next Questions: Novel Transplant and Post-Transplant Options in Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2022 08; 22(8):569-574.  View on PubMed
  14. Huang LW, Sheng Y, Andreadis C, Logan AC, Mannis GN, Smith CC, Gaensler KML, Martin TG, Damon LE, Huang CY, Olin RL. Patterns and Predictors of Functional Decline after Allogeneic Hematopoietic Cell Transplantation in Older Adults. Transplant Cell Ther. 2022 06; 28(6):309.e1-309.e9.  View on PubMed
  15. On S, Rath CG, Lan M, Wu B, Lau KM, Cheung E, Alegria W, Young R, Tan M, Kim C, Phun J, Patel N, Mannis G, Logan AC, Kennedy V, Goodman A, Taplitz RA, Young PA, Wen R, Saunders IM. Characterisation of infections in patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent. Br J Haematol. 2022 04; 197(1):63-70.  View on PubMed
  16. Cutler C, Lee SJ, Arai S, Rotta M, Zoghi B, Lazaryan A, Ramakrishnan A, DeFilipp Z, Salhotra A, Chai-Ho W, Mehta R, Wang T, Arora M, Pusic I, Saad A, Shah NN, Abhyankar S, Bachier C, Galvin J, Im A, Langston A, Liesveld J, Juckett M, Logan A, Schachter L, Alavi A, Howard D, Waksal HW, Ryan J, Eiznhamer D, Aggarwal SK, Ieyoub J, Schueller O, Green L, Yang Z, Krenz H, Jagasia M, Blazar BR, Pavletic S. Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study. Blood. 2021 12 02; 138(22):2278-2289.  View on PubMed
  17. Banerjee R, Lo M, Klein L, Aras M, Logan AC. Anthracyclines in a patient with acute leukemia and severe cardiomyopathy requiring mechanical support: A case report. J Oncol Pharm Pract. 2022 Apr; 28(3):729-732.  View on PubMed
  18. Wang VE, Blaser BW, Patel RK, Behbehani GK, Rao AA, Durbin-Johnson B, Jiang T, Logan AC, Settles M, Mannis GN, Olin R, Damon LE, Martin TG, Sayre PH, Gaensler KM, McMahon E, Flanders M, Weinberg V, Ye CJ, Carbone DP, Munster PN, Fragiadakis GK, McCormick F, Andreadis C. Inhibition of MET Signaling with Ficlatuzumab in Combination with Chemotherapy in Refractory AML: Clinical Outcomes and High-Dimensional Analysis. Blood Cancer Discov. 2021 09; 2(5):434-449.  View on PubMed
  19. Shah BD, Bishop MR, Oluwole OO, Logan AC, Baer MR, Donnellan WB, O'Dwyer KM, Holmes H, Arellano ML, Ghobadi A, Pagel JM, Lin Y, Cassaday RD, Park JH, Abedi M, Castro JE, DeAngelo DJ, Malone AK, Mawad R, Schiller GJ, Rossi JM, Bot A, Shen T, Goyal L, Jain RK, Vezan R, Wierda WG. KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results. Blood. 2021 07 08; 138(1):11-22.  View on PubMed
  20. Ngai LL, Ma CY, Maguire O, Do AD, Robert A, Logan AC, Griffiths EA, Nemeth MJ, Green C, Pourmohamad T, van Kuijk BJ, Snel AN, Kwidama ZW, Venniker-Punt B, Cooper J, Manz MG, Gjertsen BT, Smit L, Ossenkoppele GJ, Janssen JJWM, Cloos J, Sumiyoshi T. Bimodal expression of potential drug target CLL-1 (CLEC12A) on CD34+ blasts of AML patients. Eur J Haematol. 2021 Sep; 107(3):343-353.  View on PubMed

Go to UCSF Profiles, powered by CTSI